Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Patients whose pancreatic cancers have defects in the BRCA/Fanconi DNA repair pathway or
other defects in homologous repair will have cancers that respond to olaparib when given in
combination with the DNA damaging agents, irinotecan, cisplatin, mitomycin C (ICM).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins